NCT07065643

Brief Summary

Obesity increases the risk of type 2 diabetes, cardiovascular disease, and certain cancers, primarily due to elevated abdominal fat storage. With nearly two-thirds of the UK population living with overweight or obesity, there is an urgent necessity for evidence-based public health guidance to promote healthy weight. Calorie deficit can facilitate weight loss and body fat reduction, leading to health benefits, such as improved blood glucose control. Current weight management advice centres on lifestyle modification, incorporating changes to diet and physical activity to support a calorie deficit. However, existing dieting recommendations fail to consider gender or age. This is a surprising oversight, as it is well established that health outcomes vary significantly between men and women across the lifespan. Further, the menopause may have an impact on fat storage linked to changes in sex hormones. Our recent research, involving both mice and humans, has indicated that females are less responsive to weight loss and fat reduction during dieting. This study aims to understand endocrine and metabolic sex-based differences in obesity and calorie restriction, with a particular focus on women's health. We plan to conduct a diet study with 75 participants, encompassing both younger and older men and women, to monitor changes in energy expenditure and body composition using gold-standard techniques, such as doubly-labelled water. Blood and abdominal fat tissue samples will be collected to investigate how sex hormones might elucidate these differences. The aim of the study is to enhance our understanding of diet and women's health to combat obesity and promote healthy ageing.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
75

participants targeted

Target at P50-P75 for not_applicable

Timeline
19mo left

Started Jul 2025

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress35%
Jul 2025Dec 2027

First Submitted

Initial submission to the registry

July 3, 2025

Completed
6 days until next milestone

Study Start

First participant enrolled

July 9, 2025

Completed
6 days until next milestone

First Posted

Study publicly available on registry

July 15, 2025

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2027

Last Updated

July 18, 2025

Status Verified

July 1, 2025

Enrollment Period

2.4 years

First QC Date

July 3, 2025

Last Update Submit

July 17, 2025

Conditions

Keywords

caloric restrictionlow calorie dietmenopauseoverweightobesityweigh lossageingenergy expenditurebody composition

Outcome Measures

Primary Outcomes (2)

  • Change in body mass expressed as weight in kilograms (kg)

    Measured using digital scale

    From baseline (day 1) to end of intervention (day 53); additional measurements taken three times a week throughout the intervention duration

  • Change in energy expenditure expressed in kilocalories per day (kcal/day)

    Measured using stable isotope method - doubly labelled water (DLW) - with urine sample collection

    From day 11 (start of the calorie-restricted diet) to the end of the intervention (day 52); with additional doses consumed on day 25 and 39

Secondary Outcomes (12)

  • Change in resting metabolic rate (RMR) expressed in kcal/day

    From day 8 (start of the maintenance diet) to end of the intervention (day 53)

  • Change in bone mineral content in grams (g)

    From day 8 (start of the maintenance diet) to end of the intervention (day 53)

  • Change in total body water (TBW) in litres (l)

    From day 11 (start of the calorie-restricted diet) to end of the intervention (day 53)

  • Change in total body density expressed in litres (l)

    From day 8 (start of the maintenance diet) to end of the intervention (day 53)

  • Change in body fat-mass percentage (%)

    From day 8 (start of the maintenance diet) to end of the intervention (day 53)

  • +7 more secondary outcomes

Other Outcomes (7)

  • Change in glycaemic control in response to caloric restriction diet

    Every day of the study (days 1-53)

  • Change in fasting concentration of glucose

    From day 8 (start of the maintenance diet) to end of the intervention (day 53)

  • Change in fasting concentration of ketones

    From day 8 (start of the maintenance diet) to end of the intervention (day 53)

  • +4 more other outcomes

Study Arms (5)

Young women

EXPERIMENTAL

Age: 18 to 40 years old

Other: Phase 1 - Maintenance DietOther: Phase 2 - Weight loss diet

Young men

ACTIVE COMPARATOR

Age: 18 to 40 years old

Other: Phase 1 - Maintenance DietOther: Phase 2 - Weight loss diet

Older women (menopause & no-HRT)

EXPERIMENTAL

Age 55-65 years, in menopause, not taking Hormonal Replacement Therapy (HRT)

Other: Phase 1 - Maintenance DietOther: Phase 2 - Weight loss diet

Older women (menopause & HRT)

EXPERIMENTAL

Age 55-65 years, in menopause, who have continuously taken oestrogen HRT for 24 months

Other: Phase 1 - Maintenance DietOther: Phase 2 - Weight loss diet

Older men

ACTIVE COMPARATOR

Age 55-65 years

Other: Phase 1 - Maintenance DietOther: Phase 2 - Weight loss diet

Interventions

3d maintenance diet (MT, fixed macronutrient composition of 15% protein, 30% fat and 55% CHO), fed to energy requirements (1.3 X RMR)

Older menOlder women (menopause & HRT)Older women (menopause & no-HRT)Young menYoung women

6 week calorie restricted high protein diet (CR, fixed macronutrient composition as 30% protein, 35% fat and 35% CHO) fed to energy requirements \[0.8 X Resting Metabolic Rate (RMR)\], with stepwise reduction of 100kcal/d at week 3 and 5

Older menOlder women (menopause & HRT)Older women (menopause & no-HRT)Young menYoung women

Eligibility Criteria

Age18 Years - 65 Years
Sexall(Gender-based eligibility)
Gender Eligibility DetailsOnly biological (cisgender) males and females
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adults (aged over 18years) who are healthy but overweight/obese (BMI 27-45kg/m2) males and females as:
  • women (age 40 or less years)
  • men (age 40 or less years)
  • women (age 55-65 years) in menopause\*; not taking Hormone Replacement Therapy (HRT)
  • men (age 55-65 years)
  • women (age 55-65 years) in menopause; taking HRT\*\*

You may not qualify if:

  • Potential volunteers will be asked to fill in a health questionnaire at the screening visit to assess their suitability for the study. This information will allow us to exclude participants.
  • weight loss medication (e.g. GLP agonists), β-blockers, antihistamines, antipsychotics, benzodiazepines, barbiturates, melatonin, Ritalin, modafinil, soporifics, hypnotics, antiepileptic drugs, diabetes medication (e.g. metformin or insulin).
  • Females who are planning to be pregnant, are pregnant or are breastfeeding
  • Anyone with coeliac disease or gluten intolerance or food allergy
  • Anyone with diagnosed T1 or T2 diabetes
  • Anyone suffering from a psychiatric disorder or any type of substance abuse
  • Anyone following a vegetarian or vegan diet
  • Anyone currently following a weight loss programme (that may be affecting lifestyle, physical activity \& diet) or undergone gastric band/reduction surgery; including GLP agonist (e.g. Semaglutide injection, Ozempic®).
  • Anyone currently participating in another research study
  • Anyone with unsuitable veins for blood sampling
  • Anyone who is unable to fluently speak, read and understand English
  • Anyone who is unable to comply to an alcohol-free diet for 6 weeks
  • Anyone unable to give fully informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Rowett Institute, University of Aberdeen

Aberdeen, United Kingdom

RECRUITING

Related Links

MeSH Terms

Conditions

OverweightObesity

Condition Hierarchy (Ancestors)

OvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Alexandra M Johnstone, Professor

    Rowett Institute, University of Aberdeen

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Alexandra M. Johnstone, Professor

CONTACT

Marta Lonnie, Dr

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
FACTORIAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 3, 2025

First Posted

July 15, 2025

Study Start

July 9, 2025

Primary Completion (Estimated)

December 1, 2027

Study Completion (Estimated)

December 1, 2027

Last Updated

July 18, 2025

Record last verified: 2025-07

Data Sharing

IPD Sharing
Will share

The study will be registered with ClinicalTrials.gov as a data repository. Links to IPD that underlie results in publications will be made available at the appropriate time through the project team's website which will contain a summary of the data compiled.

Shared Documents
STUDY PROTOCOL, SAP, ICF, CSR
Time Frame
Data will be shared with the academic community once this has been published in open access journals
Access Criteria
Open access from the project's website to IPD that underline the results reported in scientific publications.

Locations